Experience of surgical treatment for hepatoblastoma  by Liu, Chinsu et al.
Formosan Journal of Surgery (2016) 49, 56e62Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e-f js .comORIGINAL ARTICLEExperience of surgical treatment for
hepatoblastoma
Chinsu Liu a,*, Hsin-Lin Tsai a, Taiwai Chin a, Choufu Wei a,ba Division of Pediatric Surgery, Department of Surgery, Taipei Veterans General Hospital,
National Yang-Ming University, Taipei, Taiwan
b Department of Surgery, National Taipei Medical University, Taipei, TaiwanReceived 10 July 2015; received in revised form 9 September 2015; accepted 8 October 2015
Available online 11 February 2016KEYWORDS
chemotherapy;
hepatoblastoma;
liver resection;
liver transplantation;
PRETEXTConflicts of interest: None.
* Corresponding author. Division of P
Hospital, Number 201, Section 2, Shih
E-mail address: csliu@vghtpe.gov.
http://dx.doi.org/10.1016/j.fjs.2015.
1682-606X/Copyright ª 2016, TaiwanAbstract Background/Introduction: Although the surgery for hepatoblastoma (HB) is the
mainstay of treatment, the surgical strategies for HB still need elucidation.
Purpose: This study evaluates the surgical results of HB in our institution since 1996, and we
discuss surgical strategies targeting HB.
Methods: Retrospective chart review.
Results: We enrolled 14 patients, of whom 12 and two were newly diagnosed and tumor recur-
rence patients, respectively. Among the 12 newly diagnosed patients, hepatectomy was per-
formed before and after chemotherapy in four and eight patients, respectively. Tumor
resectability was strongly dependent on the surgeon’s experience in three cases, achieving
long-term tumor-free survival in these patients. One of eight patients with a definite resectable
tumor had recurrent HB and received live donor liver transplantation (LDLT) immediately after
recurrence, subsequently achieving long-term tumor-free survival. One patient with a definite
resectable tumor died because of a congenital heart anomaly. Long-term tumor-free survival
was achieved in 91.7% of the newly diagnosed patients. For the two patients referred for recur-
rence, LDLTwas performed on one patient with recurrent HB, although recurrence was observed
4 months after the transplant, and the patient died because of cachexia 1 year after receiving
LDLT. A liver autotransplant was performed on the other referred patient with HB recurrence,
which failed because of abdominal compartment syndrome.
Conclusion: A careful complete resection of HB combinedwith aggressive chemotherapy can yield
long-term survival inmost patients with HB. Liver transplantation should be performed in patients
with unresectable tumors and tumor recurrence immediately after recurrence. Repeat hepatec-
tomy is not recommended if a live donor is available.
Copyright ª 2016, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.ediatric Surgery, Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General
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Surgical treatment of hepatoblastoma 571. IntroductionHepatoblastoma (HB) is the most commonly occurring ma-
lignant liver tumor in children, with an incidence of 0.7e1/
million children < 15 years of age in Western countries.1 In
Taiwan, HB has become the most common malignant he-
patic tumor in children in the past 2 decades after a
nationwide hepatitis B vaccination program was imple-
mented in 1984.2 Advances in chemotherapy and advance-
ments in surgical techniques have improved the cure rate of
HB to up to 75e80%.3 However, performing a complete
surgical resection remains the most crucial intervention for
achieving a cure, and only 60% of tumors are resectable
when diagnosed.4 Adjuvant chemotherapy and liver trans-
plantation are alternative modes of treatment for curative
therapy in patients with initially unresectable tumors.5 In
this retrospective study, we evaluated surgical strategies
for HB based on our experiences.
2. Materials and methods
We retrospectively reviewed the outcomes of patients with HB
who received surgical treatment at our institution since 1996.
Tumor staging was performed according to the pretreatment
extension (PRETEXT) system designed by the International
Childhood Liver Tumor Strategy Group, with the stages cate-
gorized as follows. Stage I: one section is involved and three
adjoining sections are free; Stage II: one or two sections are
involved, but two adjoining sections are free; Stage III: two or
three sections are involved, and no two adjoining sections are
free; and Stage IV: all four sections are involved.6,7 The pro-
tocol for evaluating tumor resectability and treatment is
depicted in Figure 1. The chemotherapy regimensweremainly
divided into two groups: a high-risk HB group [cisplatin 80 g/
m2/d if bodyweight > 10 kg, or 2.6 mg/kg/d if body-
weight < 10 kg in combination with carboplatin 500 mg/m2/
d (16.6 mg/kg if < 10 kg) and doxorubicin 30 mg/m2/d intra-
venous dripping for 24 hours] and a nonhigh-risk HB group
(cisplatin 80 g/m2/d if bodyweight > 10 kg or 2.6 mg/kg/d if
bodyweight < 10 kg in combination with doxorubicin 30 mg/
m2/d). The inclusion criteria for the high-risk HB group were
any of the following: tumor involving all four hepatic sections
(PRETEXT Stage IV), presence of distant metastases, tumor
extension into the vena cava or all three hepatic veins, tumor
extension into the main or both branches of the portal vein,
biopsy evidence for extrahepatic intraabdominal disease, pa-
tients with initial low serum alpha-fetoprotein (AFP)
level < 100 ng/mL, and tumor rupture at presentation. A
follow up after liver resection was conducted chiefly by a pe-
diatric oncologist. The strategy included regular follow ups for
AFP levels, abdominal or chest computed tomography, cardiac
echocardiography, and renal functions 4 times/y in Post-
operative Year 1, and then gradually decreasing the follow-up
frequency until Postoperative Year 5. If recurrence was noted,
a repeat resection or liver transplantation was considered.
3. Results
Werecruited14patients (11malesand3 females),whosecases
were followed for amean of 10.8 years (5e19 years;median of9 years). Of these patients, 12 and two were newly diagnosed
and referred patients with tumor recurrence, respectively.
The mean age of the newly diagnosed patients was 18 months
(2e36months), and the ages of the two referred patients with
tumor recurrences were 4 years and 13 years. Three of the
patients were twins (21.4%, 3/14). The AFP level before
treatmentwas>100,000ng/mL in13 (92.8%)patients, andwas
moderately higher in one patient (87 ng/mL).
All of the newly diagnosed patients received a hepatec-
tomy; fourbeforeandeight after chemotherapy. Basedon the
author’s experience, six tumors of the PRETEXT Stage II were
considered resectable before chemotherapy. Three tumors of
the PRETEXTandposttreatment extension (POSTTEXT) Stages
of IV and II, respectively, which were initially unresectable,
were considered resectable after chemotherapy. In three
patients, the resectability of the tumors of the PRETEXT Stage
IV and POSTTEXT Stages III or IV was controversial and highly
dependent on the surgeon’s experience (Figures 2e4). In one
patient with distal lung metastasis (8.3%), the lung lesions
disappeared after neoadjuvant chemotherapy, as proven by
exploratory thoracotomy, and the patient subsequently
received a hepatectomy. Furthermore, two, six, and four
patients received left, right, and extended right lobectomies,
respectively. Hepatic resection in two patients resulted in
complicationsofbile leakage,and recoverywasaccomplished
through pigtail drainage. One patient with a right lobectomy
after chemotherapy had recurrent HB on the left lobe, and
received live donor liver transplantation (LDLT) immediately
after recurrence, achieving long-term tumor-free survival
(case followed for 8 years). Another patient (trisomy 18)
received a hepatectomy after chemotherapy, but died
because of a congenital heart disease 1 year after a hepa-
tectomy without tumor recurrence. Therefore, long-term
tumor-free survival was achieved in 91.7% of our newly diag-
nosed patients.
One referred patient with tumor recurrence was a 4-year-
old boy who had received chemotherapy, and subsequently, a
hepatectomy and wedge resection of his lung for lung
metastasis at the age of 2 years. He was referred to our hos-
pital for liver transplantation after tumor recurrence. After
performing detailed examinations to rule out distant metas-
tasis, he receivedLDLT.However, tumor recurrencewasnoted
on the liver graft 4 months after transplantation, and he died
1 year after receiving it. The other referred patient was a 13-
year-old boy who received a hepatectomy five times, and his
renal function was impaired because of large dose chemo-
therapy. He was referred to our institution for liver trans-
plantation because of tumor recurrence in the right
diaphragmand inferior vena cava. The author considered that
an allograft liver transplant would have a high risk of recur-
rence, and that liver resection and en bloc resection of the
involved vena cava would lead to difficulties in controlling
bleeding and reconstructing the venous return of the lower
torso and left hepatic vein. Therefore, liver auto-
transplantation was performed (Figure 5). In brief, the
affected liver was removed en bloc along with the retro-
hepatic vena cava and diaphragm. The vena cava was then
reconstructed using an artificial graft, and the portal vein was
implanted to the artificial graft to decompress the portal
system temporarily. Theaffected liverwas thenflushedwitha
chilled preservation solution, and the section with the tumor
was removed through a back-table procedure. The
Figure 1 Protocol for evaluating tumor resectability and treatment. AFP Z alpha-fetoprotein; CT Z computed tomography;
MRI Z magnetic resonance imaging.
58 C. Liu et al.reconstructed left hepatic vein outflowwith the residual vena
cava was implanted into the artificial vena cava graft in an
end-to-side manner. The portal and hepatic arterial inflows
were reconstructed in an end-to-end manner, and a biliary
reconstruction was also performed in a duct-to-duct manner.
The operation required 10 hours with a blood loss of 400 cm3,
and the operative course was smooth. However, abdominal
compartment syndrome occurred after closure of the
abdomen, causing graft necrosis. Thepatient died 9 days after
the operation.4. Discussion
HB is the most common hepatic malignancy in children,
accounting for approximately 80% of all malignant livertumors, and it typically presents in children aged <3 years,
as an abdominal mass combined with failure to thrive and
anemia.6 Although the outcome of HB was poor 3 decades
ago, long-term survival rates can currently reach up to
75e80%, mainly because of advances in chemotherapy and
improved surgical decision-making.3 A complete surgical
resection is the major treatment for curing HB; however,
only approximately 60% of tumors are resectable when
diagnosed.4 The decision of tumor resectability without
chemotherapy (PRETEXT) or after several courses of
chemotherapy (POSTTEXT) requires a thorough review of
the contrast-enhanced computed tomographic angiography
and magnetic resonance imaging scans, along with the
surgeon’s knowledge of liver anatomy and surgical ability
for ensuring a complete resection without injuring the
vascular inflow and outflow of the remaining liver.8
Figure 2 Case 1 of three patients with tumors of posttreatment extension (POSTTEXT) Stage III or IV. (A) Prechemotherapy
imaging study showed that the tumor was at pretreatment extension (PRETEXT) Stage IV and involved four liver sections. (B) (1, 2)
After four courses of chemotherapy, the imaging study showed that the tumor improved to POSTTEXT Stage III and involved three
sections, excluding only the left lateral section of the liver. (C) Diagram showing the tumor extent. A complete resection was
performed with a total operative blood loss of 80 cm3.
Surgical treatment of hepatoblastoma 59Performing a complete resection in patients with the
PRETEXT or POSTTEXT Stage I or II tumors is not difficult for
pediatric surgeons who can perform liver resections. Sur-
geons should attempt to avoid unnecessary strong dose
chemotherapy regimens for such patients, specifically for
those with tumors of PRETEXT Stages I and II. An aggressive
resection is also not recommended. Patients with tumors of
PRETEXT Stage III or IV should receive down staging neo-
adjuvant chemotherapy for at least four cycles, for which
cisplatin, vincristine, 5-fluorouracil, cyclophosphamide,
and doxorubicin are among the most usefulchemotherapeutic agents, and then have their tumor
staging reevaluated for resectability.5 If the tumor stage
improves to POSTTEXT Stage II, a complete resection should
be performed, and adjuvant chemotherapy is strongly
recommended for completing the therapy. However, the
interpretation of resectability is highly dependent on the
surgeon’s experience. For example, resectability for a
unifocal, centrally located Stage II tumor involving the main
hilar structures should be considered debatable. Two more
cycles of neoadjuvant chemotherapy are then recom-
mended for further down staging if the tumor is susceptible
Figure 3 Case 2 of three patients with tumors of posttreat-
ment extension (POSTTEXT) Stage III or IV. (A) After four
courses of chemotherapy, the imaging study showed that the
tumor was at pretreatment extension (PRETEXT) Stage IV and
involved four liver sections. (B) After six courses of chemo-
therapy, the imaging study showed that the tumor improved to
PRETEXT Stage III and involved three sections with partial
involvement of the left medial section. (C) Diagram shows the
tumor extent. A complete resection was performed with a total
operative blood loss of 300 cm3.
Figure 4 Case 3 of three patients with tumors of posttreat-
ment extension (POSTTEXT) Stage III or IV. (A) Pre-
chemotherapy imaging study showed that the tumor was at
pretreatment extension (PRETEXT) Stage IV and involved four
liver sections. (B) After six courses of chemotherapy, the im-
aging study showed that the tumor improved to POSTTEXT
Stage IV and involved four sections with partial involvement of
the left lateral section, particularly involving the left hepatic
vein. (C) Diagram shows the tumor extent.
60 C. Liu et al.to chemotherapy, which is evidenced by decreasing AFP
levels or an evident shrinkage of the tumor.
For patients with tumors interpreted as Stage III or IV,
even after four cycles of neoadjuvant chemotherapy,
whether two more cycles of chemotherapy are to be
administered, surgeons should rely on the response to
Figure 5 Liver autotransplantation in a patient who received
multiple hepatectomies. (A) The imaging study showed tumor
recurrence in the right diaphragm and IVC. (B) Diagram showing
the tumor extent. (C) The tumor was removed through a back-
table procedure. (D) The image of completed auto-
transplantation displayed the desired liver color. The operation
required 10 hours, with a blood loss of 400 cm3, and the operative
course was smooth. IVCZ inferior vena cava; LHVZ left hepatic
vein; PVZ portal vein.
Surgical treatment of hepatoblastoma 61chemotherapy; if the response is obvious, two more cy-
cles of chemotherapy should be considered. The three
newly diagnosed patients had tumors of POSTTEXT Stage
III or IV, two of whom received two more cycles of neo-
adjuvant chemotherapy because of the satisfactory
response to the previous four cycles of chemotherapy.
One patient with a POSTTEXT Stage III tumor did not
receive two more cycles of neoadjuvant chemotherapy,
because of the unsatisfactory response to the previous
chemotherapy.
Advising surgical treatment for tumors of POSTTEXT
Stage III or IV without further neoadjuvant chemotherapy is
challenging. Although performing a complete resection can
still be possible if the tumor remains at Stage III or IV,9
which is highly dependent on the surgeon’s ability, liver
transplantation is recommended for patients with unre-
sectable Stage III or IV tumors10 because the outcome of
rescue liver transplantation is poor. In our three newly
diagnosed patients with tumors of POSTTEXT Stage III or IV,
extremely careful dissection of the portal structure and
hepatic vessels was a key factor for a successful complete
tumor resection. We strongly recommend that patients
with tumors of POSTTEXT Stage III or IV be referred to
surgeons familiar with liver transplantation. However, sur-
gery of HB resulting in an incomplete resection is
discouraged.
Liver autotransplantation for HB has yet to be reported.
Although our limited experience with only one case cannot
be relied upon to reach any conclusions, this type of surgery
may be considered for patients with unresectable HB, with
tumors of either POSTTEXT Stage III or IV, or those in the
major vessels, when no liver donors are available, because
the technique is reproducible only by experienced pediatric
liver transplant surgeons.
In conclusion, if patients with HB are diagnosed with
accurate tumor staging and treated with adequate adju-
vant and neoadjuvant chemotherapies and appropriate
surgery, the outcomes are most favorable with a tumor-free
survival rate of up to 80%.References
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